Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16 avr. 2024 04h35 HE
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 avr. 2024 08h05 HE
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
09 avr. 2024 16h00 HE
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Aegion Announces Acquisition of Toncco
27 mars 2024 11h00 HE
|
Aegion Corp
Aegion Corporation today announced the acquisition of Toncco, an underground utilities company based in Ogden, Utah.
Boehringer expands production site in Greece for new medicine
11 janv. 2024 10h15 HE
|
Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
08 janv. 2024 07h00 HE
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes
13 déc. 2023 05h07 HE
|
Everzom
EVerZom : Ambition thérapeutique dans les biothérapies à base d’exosomes Lauréat de l’EIC Accelerator pour sa plateforme d’innovation technologique, EVerZom dévoile son pipeline propriétaire de...
EVerZom: Therapeutic Ambition in Exosome Biotherapies
13 déc. 2023 05h07 HE
|
Everzom
EVerZom: Therapeutic Ambition in Exosome Biotherapies EVerZom, winner of the EIC Accelerator for its breakthrough technology platform, presents its proprietary pipeline of exosome-based...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
03 nov. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
Aegion Announces Acquisition of Portland Utilities Construction Company, LLC
31 juil. 2023 08h53 HE
|
Aegion Corp
ST. LOUIS, July 31, 2023 (GLOBE NEWSWIRE) -- Aegion Corporation, a leading provider of infrastructure maintenance, rehabilitation and technology-enabled water solutions, today announced the...